The article reviews the multifaceted role of myocardial infarction-associated transcript (MIAT), a long non-coding RNA (lncRNA), in hepatocellular carcinoma (HCC). MIAT has been identified as a regulator of carcinogenesis in various malignant tumors, with its overexpression predicting poor prognosis. At the molecular level, MIAT is linked to the initiation of metastasis, invasion, cellular migration, and proliferation. The authors provide a comprehensive overview of the underlying molecular mechanisms of MIAT, including its downstream target genes, interaction with other ncRNAs, and potential clinical implications as a diagnostic and/or prognostic biomarker in HCC. They highlight the complex regulatory mechanisms of MIAT, its involvement in chronic liver diseases, and its role in HCC chemoresistance and immunotherapy. The article also discusses the potential clinical applications of MIAT, such as its use as a diagnostic biomarker and therapeutic target. However, the authors acknowledge the limitations of current research, including the need for more detailed mechanisms and clinical studies to establish MIAT's potential in HCC.The article reviews the multifaceted role of myocardial infarction-associated transcript (MIAT), a long non-coding RNA (lncRNA), in hepatocellular carcinoma (HCC). MIAT has been identified as a regulator of carcinogenesis in various malignant tumors, with its overexpression predicting poor prognosis. At the molecular level, MIAT is linked to the initiation of metastasis, invasion, cellular migration, and proliferation. The authors provide a comprehensive overview of the underlying molecular mechanisms of MIAT, including its downstream target genes, interaction with other ncRNAs, and potential clinical implications as a diagnostic and/or prognostic biomarker in HCC. They highlight the complex regulatory mechanisms of MIAT, its involvement in chronic liver diseases, and its role in HCC chemoresistance and immunotherapy. The article also discusses the potential clinical applications of MIAT, such as its use as a diagnostic biomarker and therapeutic target. However, the authors acknowledge the limitations of current research, including the need for more detailed mechanisms and clinical studies to establish MIAT's potential in HCC.